SCHEMBL365659

SCHEMBL365659

COc1ccc(Cn2cc3c(n2)CCCCCC3=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
AADAT Q8N5Z0 1/20 0.48
CMA1 P23946 1/20 0.44
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
USP2 O75604 1/20 0.41
CYP11B2 P19099 1/20 0.41
ELANE P08246 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
BCHE P06276 1/20 0.39
LMNA P02545 1/20 0.39
CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837301 1.00 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL366655 0.86 AADAT (0.46) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL367366 0.84 AADAT (0.47) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL365853 0.82 AADAT (0.45) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL6837143 0.82 AADAT (0.45) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL365004 0.82 AADAT (0.43) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL366071 0.82 AADAT (0.50) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL7670133 0.82 AADAT (0.47) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL365744 0.82 AADAT (0.47) ALDH1A1SMN1; SMN2POLBAADATCMA1
SCHEMBL366198 0.82 AADAT (0.42) ALDH1A1SMN1; SMN2POLBAADATCMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 ALDH1A1 3331/4885SMN1; SMN2 2061/4885POLB 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.